吸入舒利迭和思力华治疗稳定期COPD疗效观察

Observation on the Effects of Salmeterol/Fluticasone Propionate and Tiotropium Inhalation Capsules in the Treatment of Stable Chronic Obstructive Pulmonary Disease

目的观察舒利迭(沙美特罗替卡松粉吸入剂)和思力华(噻托溴铵粉吸入剂)联合吸入治疗稳定期慢性阻塞性肺疾病(COPD)的疗效。方法 76例稳定期COPD患者随机分成两组,治疗组38例,吸入舒利迭50μg/250μg/次,2次/d,思力华18μg/次,1次/d;对照组38例,仅吸入舒利迭50μg/250μg/次,2次/d,治疗12周后判定疗效。结果 72例患者完成实验,治疗组在临床有效率、动脉血气及肺功能的改善方面明显优于对照组(P<0.05),用药过程中未出现严重不良反应。结论联合吸入舒利迭和思力华治疗稳定期COPD患者,可以明显改善临床症状及肺功能,效果优于单用舒利迭。

Objective To study the efficacy of salmeterol/fluticasone propionate（Seretide） and tiotropium inhalation capsules in patients with stable chronic obstructive pulmonary disease（COPD）. Methods 76 patients with stable COPD were randomly divided into 2 groups. 38 patients in treatment group（seretide ＋ tiotropium）,They were given Seretide （250μg/50μg） inhaling twice daily and tiotropi- urn bromide（18μg） inhaling once daily. 38 patients in control group,They were given Seretide（250μg/50μg） inhaling twice daily. The treatment was last for 12 weeks. Before and after the cause of treatment,Arterial blood gas and lung function of the two groups were examined and compared respectively. Results 72 patients completed the study. The improvement of effective rate,arterial blood gas and lung function in treatmem group are better than the control group. No adverse reaction during treatment. Conclusion The combination of seretide and tiotropium can obviously improve clinical symptoms and lung function of the patients with stable COPD. The effects of combination of seretide and tiotropium is better than only seretide.